Durable disease control following multidisciplinary treatment including pembrolizumab in POLE-mutated dedifferentiated endometrial carcinoma with brain metastases: A case report.
Takumi Ito, Jumpei Yoshida, Akari Iwakoshi et al.
✦ AI-curated · Sources linked
Case in brief
A 58-year-old woman with POLE-mutated dedifferentiated endometrial carcinoma presented with headache, dizziness, and weakness due to multiple brain and pulmonary metastases. Diagnosis was confirmed via endometrial biopsy and genomic profiling. Following urgent cerebellar resection and radiotherapy, she received systemic therapy with carboplatin, paclitaxel, and pembrolizumab, leading to significant regression of lesions and complete resolution of symptoms. At 14 months, she remained progression-free.
Diagnostic / clinical pearl
Molecular profiling, particularly for POLE mutations, can identify patients with dedifferentiated endometrial carcinoma who may respond favorably to immunotherapy, even in the context of aggressive disease.